Surgery Partners Inc

Surgery Partners Inc(SGRY)股票分析

$14.610

-0.158 (-1.08%)收盘时

Loading chart…
最高
14.900
开盘
14.860
成交量加权均价
14.67
成交量
966.82K
市值
3.09B
最低
14.510
成交额
14.19M
企业价值/息税折旧摊销前利润(TTM)
10.21

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals.

AI 分析 of Surgery Partners Inc (SGRY)

买入

Surgery Partners Inc is a good buy right now due to its current price of $13.89 being significantly lower than the median analyst price target of $19, suggesting a potential upside of 35.9%. Additionally, the stock has shown a recent positive momentum with a 5-day change of +4.28% and insider buying activity, as a director increased her stake by 20%. However, the company does face risks, including a significant debt burden of $4 billion and a net loss of $88.6 million, which could impact future performance.

分析师评级(9)

上行空间 +80.01%
买入
4 买入
4 持有
1 卖出
当前: 14.61
最低
18.00
平均
26.30
最高
36.00

JPMorgan

2026-09-14

目标价

$15

中性

RBC Capital

2026-08-11

目标价

$19

跑赢大盘

TD Cowen

2026-08-11

目标价

$19

买入

Cantor Fitzgerald

2026-08-11

目标价

$18

增持

Jefferies

2026-05-06

目标价

$17

买入

估值指标

Surgery Partners Inc(SGRY)当前预期市盈率为 18.90,5 年平均预期市盈率为 74.59。

预期市盈率

合理
5 年均值 P/E
74.59
当前P/E
18.90
高估
212.63
低估
-63.45

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
15.73
当前EV/EBITDA
10.21
高估
20.00
低估
11.47

预期市销率

合理
5 年均值 P/S
1.09
当前P/S
0.69
高估
1.50
低估
0.69

Alphio AI 对 SGRY 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SGRY

$22.84

情景价格

基

基准

基准 · 50%SGRY

$21.90

情景价格

悲

悲观

悲观 · 25%SGRY

$21.04

情景价格

持有 SGRY 的大户

J

Jaunty Global Limited

+ 持有SGRY

-1.42%

3个月收益率

事件时间线

2026-08-23 (ET)

00:00:00

Charter Communications Short Interest Rises to 32.4%

2026-08-10 (ET)

17:00:00

Stocks Open Lower as Middle East Uncertainty Grows

12:30:00

Major Averages Mixed at Open Amid Middle East Uncertainty

08:00:00

Company Reports Q2 Revenue of $848.9M, Exceeds Expectations

08:00:00

Company Reaffirms 2026 Revenue Outlook of $3.35B to $3.45B

资讯

SGRY 常见问题 —— 由 Alphio AI 解答

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

Surgery Partners Inc is a good buy right now due to its current price of $13.89 being significantly lower than the median analyst price target of $19, suggesting a potential upside of 35.9%. Additionally, the stock has shown a recent positive momentum with a 5-day change of +4.28% and insider buying activity, as a director increased her stake by 20%. However, the company does face risks, including a significant debt burden of $4 billion and a net loss of $88.6 million, which could impact future performance.

9 analysts cover SGRY: 4 rate it Buy, 4 Hold and 1 Sell. The average price target is 26.30.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易